Straits Times Index
3,330.81 +0.80 (+0.02%) S&P 500
5,352.57 -1.46 (-0.03%) Dow
38,892.93 +85.60 (+0.22%) Nasdaq
17,169.60 -18.31 (-0.11%) Bitcoin USD
71,081.93 +33.49 (+0.05%) CMC Crypto 200
1,519.16 -5.65 (-0.37%)
NVO Jul 2024 185.000 call
- Investing.com
Shares in Wegovy-maker Novo Nordisk climb, touching record high levels
Investing.com -- Copenhagen-listed shares in Novo Nordisk (CSE:NOVOb) edged up by 3.8% on Thursday, touching a fresh record high.
- Reuters
Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China
SHANGHAI (Reuters) -Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are developing at least 15 generic versions of its diabetes drug Ozempic and weight loss treatment Wegovy, clinical trial records showed. The Danish drugmaker has high hopes that demand for its blockbuster drugs will surge in China, which is estimated to have the world's highest number of people who are overweight or obese. Ozempic won approval from China in 2021 and Novo Nordisk saw sales of the drug in the greater China region double to 4.8 billion Danish Krone ($698 million) last year.
- Reuters
Novo Nordisk braces for challenge to Ozempic and Wegovy from wave of generics in China
SHANGHAI (Reuters) -Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are developing at least 15 generic versions of its diabetes drug Ozempic and weight loss treatment Wegovy, clinical trial records showed. The Danish drugmaker has high hopes that demand for its blockbuster drugs will surge in China, which is estimated to have the world's highest number of people who are overweight or obese. Ozempic won approval from China in 2021 and Novo Nordisk saw sales of the drug in the greater China region double to 4.8 billion Danish Krone ($698 million) last year.
